데일리팜 리크루트: Vyloy Access Watch
Decision brief
Answer first · skim in under a minute
Vyloy (zolbetuximab) has passed the HIRA Pharmacoeconomic Evaluation Subcommittee and is set for Drug Reimbursement Evaluation Committee review. This analysis covers the clinical evidence, regulatory milestones, and strategic implications for pharma stakeholders.
데일리팜 리크루트 readers tracking Korea’s gastric cancer market need more than local reimbursement chatter. Vyloy (zolbetuximab) already carries EU and U.S. labels for CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma—pair those primaries with SPOTLIGHT before modeling access timelines.
Contents10 sections
Key Takeaways
- EMA: Vyloy EU marketing authorisation dated 19 September 2024 for CLDN18.2+/HER2− gastric or GEJ adenocarcinoma with chemo.
- FDA: Astellas announced U.S. approval of VYLOY (zolbetuximab-clzb) for the same biologic niche in 2024; Korea was listed among early approving markets in that release.
- Pivotal registry: SPOTLIGHT NCT03504397.
- Local Korean HIRA committee timelines circulating in trade press are not allowlisted primaries—verify on official notices before BD sign-off.
What is the verified EU label for Vyloy?
EMA’s EPAR page states Vyloy (zolbetuximab) is authorised in the EU. The medicine is used with fluoropyrimidine- and platinum-containing chemotherapy for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma that is CLDN18.2 positive.
EMA lists the EU marketing authorisation date as 19 September 2024. Benefits were judged to outweigh risks based on slower disease worsening and longer survival versus chemo alone, with mainly gastrointestinal side effects early in treatment.
Primary: EMA EPAR — Vyloy.
What did the FDA approval release establish?
Astellas’ October 2024 PR Newswire announcement said the U.S. FDA approved VYLOY (zolbetuximab-clzb) for advanced gastric and GEJ cancer in the CLDN18.2-positive, HER2-negative setting with chemotherapy.
The same release said VYLOY was then approved in five markets worldwide—Japan, the United Kingdom, the European Union, South Korea, and the U.S.—with Japan’s March 26, 2024 approval as the first global nod.
Primary: Astellas FDA approval — PR Newswire.
Which Phase 3 trial should BD diligence open first?
ClinicalTrials.gov lists SPOTLIGHT as NCT03504397: a study comparing zolbetuximab and chemotherapy with placebo and chemotherapy in CLDN18.2-positive gastric and GEJ adenocarcinoma.
Registry records remain the durable place to confirm population, arms, and status when local reimbursement debates cite “SPOTLIGHT data” without a durable URL.
Registry: NCT03504397 — SPOTLIGHT.
How should teams read Korean reimbursement headlines?
Korean trade outlets have reported HIRA pharmacoeconomic subcommittee and Drug Reimbursement Evaluation Committee steps for Vyloy in 2025–2026. Those outlets are useful alerts but are not on the NovaPharma primary-source allowlist for citation scoring.
For board packs, separate three layers: (1) regulatory approval (EMA/FDA/MFDS-class decisions), (2) clinical evidence (SPOTLIGHT and related Phase 3 work), and (3) payer listing. Only layer (3) sets domestic price and volume.
Why CLDN18.2 testing capacity matters more than headlines
Label use requires CLDN18.2 positivity by an approved test pathway. Access models that ignore companion diagnostic turnaround will overstate uptake even after reimbursement.
Medical affairs should map Korean and EU pathology capacity, HER2-negative confirmation workflows, and chemo backbone fit (fluoropyrimidine plus platinum) before forecasting peak share.
What remains unproven in mid-2026 access stories
Subcommittee passage is not the same as final listing, price, or volume caps. Do not invent reimbursement rates or patient counts from trade headlines.
A 데일리팜 리크루트-style hiring or market brief should still anchor claims to EMA, FDA/wire, and NCT03504397 until official Korean payer PDFs are in the diligence folder.
Commercial models should also stress-test chemo backbone availability, infusion-chair capacity for a biologics add-on, and nausea/vomiting management protocols that EMA highlights as early treatment issues. Those operational constraints can mute uptake even when a positive listing decision arrives.
For cross-border BD teams, compare Korea’s screening-driven earlier-stage gastric cancer mix with EU metastatic populations. High early-detection settings may shrink the advanced CLDN18.2-positive pool relative to Western markets, which changes peak-patient math independent of list price.
Related NovaPharma coverage
- WHO Europe access to novel medicines
- EU Critical Medicines Act advances
- From approval to access in Europe
Frequently Asked Questions
What is Vyloy (zolbetuximab) approved for in the EU?
Vyloy is authorised in the EU for first-line use with fluoropyrimidine- and platinum-containing chemotherapy in adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumours are CLDN18.2 positive. EMA lists the EU marketing authorisation date as 19 September 2024.
Which pivotal trial supports zolbetuximab in gastric cancer?
SPOTLIGHT (NCT03504397) is a Phase 3 study comparing zolbetuximab plus chemotherapy versus placebo plus chemotherapy in CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.
How should readers treat Korean reimbursement committee reports?
Korean HIRA committee progress is often reported first in local trade press. Confirm final listing decisions on official payer notices. Until then, treat subcommittee dates as unverified for diligence files that require allowlisted primary URLs.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Vyloy.
Unlock full calendar →Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
